The Evolving Role of ctDNA-Based Minimal Residual Disease Testing in Immunotherapy for Muscle-Invasive Bladder Cancer

Panelists discuss new findings on adjuvant immunotherapy for high-risk bladder cancer revealing significant insights into patient outcomes and treatment strategies.

Panelists explore the latest insights on CTDNA in muscle-invasive bladder cancer and its impact on immunotherapy decision-making and patient outcomes.

Drs. Meeks and Tan explore the SunRISe-4 trial, highlighting its innovative combination of intravesical therapy and immunotherapy.

The panelists propose a nuanced view of molecular testing, suggesting ctDNA's value lies in its positive predictive capacity for identifying advanced disease, while utDNA may offer stronger negative predictive insights.

The discussion centers on the Imvigor011 trial, comparing its ctDNA-guided intervention approach to prostate cancer monitoring. Dr. Meeks and Dr. Tan explore how this prospective study could transform adjuvant therapy strategies in muscle-invasive bladder cancer (MIBC).

The panelists investigate emerging molecular testing technologies, focusing on whole genome sequencing and advanced profiling techniques.

The experts conclude this program by discussing future biomarker-guided approaches in bladder cancer treatment.